Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus.
Emma M KileelJanet LoCarlos D MalvestuttoKathleen V FitchMarkella V ZanniCarl J FichtenbaumEdgar Turner OvertonNwora Lance OkekePrincy KumarEsau JoaoJudith A AbergEsteban MartinezJudith S CurrierPamela S DouglasHeather J RibaudoSteven K GrinspoonPublished in: Open forum infectious diseases (2021)
Differences in weight and waist circumference associated with INSTI use are (1) not uniform across people with human immunodeficiency virus, (2) greatest among women and nonwhites, and (3) concentrated at the upper tails of weight distribution. These data identify at-risk subgroups for whom long-term cardiovascular disease outcomes should be carefully assessed.
Keyphrases
- human immunodeficiency virus
- body mass index
- weight gain
- weight loss
- cardiovascular disease
- body weight
- hepatitis c virus
- antiretroviral therapy
- hiv infected
- physical activity
- type diabetes
- polycystic ovary syndrome
- insulin resistance
- metabolic syndrome
- electronic health record
- hiv aids
- hiv positive
- magnetic resonance
- big data
- pregnancy outcomes
- high fat diet induced
- contrast enhanced
- magnetic resonance imaging
- cardiovascular events
- deep learning
- cardiovascular risk factors
- artificial intelligence
- glycemic control
- coronary artery disease
- breast cancer risk